{ "labelLang" : "hun", "responseDate" : "2024-03-29 07:07", "content" : { "otype" : "JournalArticle", "mtid" : 33617075, "status" : "VALIDATED", "published" : true, "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2024-03-08T12:38:01.361+0000", "lastModified" : "2023-03-16T09:12:49.087+0000", "created" : "2023-02-03T14:44:29.647+0000", "creator" : { "otype" : "Author", "mtid" : 10076178, "link" : "/api/author/10076178", "label" : "Bokhari Syeda Mahak Zahra (Orvosi tudományok)", "familyName" : "Bokhari", "givenName" : "Syeda Mahak Zahra", "published" : true, "snippet" : true }, "lastDuplumSearch" : "2023-12-04T10:54:18.118+0000", "validated" : "2023-02-07T07:41:28.971+0000", "validator" : { "otype" : "Admin", "mtid" : 10080205, "link" : "/api/admin/10080205", "label" : "Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin)", "familyName" : "Szalóky-Siki", "givenName" : "Ágnes", "published" : true, "snippet" : true }, "core" : true, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 1134514, "link" : "/api/subtype/1134514", "label" : "Összefoglaló cikk (Folyóiratcikk)", "name" : "Összefoglaló cikk", "nameEng" : "Survey paper", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 102, "published" : true, "oldId" : 1134514, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Dora, David", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 106568190, "link" : "/api/authorship/106568190", "label" : "Dora, David ✉ [Dóra, Dávid (Fejlődésbiológia), szerző] Anatómiai, Szövet- és Fejlődéstani Intézet (SE / AOK / I)", "listPosition" : 1, "share" : 0.125, "first" : true, "last" : false, "corresponding" : true, "author" : { "otype" : "Author", "mtid" : 10050618, "link" : "/api/author/10050618", "label" : "Dóra Dávid (Fejlődésbiológia)", "familyName" : "Dóra", "givenName" : "Dávid", "published" : true, "oldId" : 10050618, "snippet" : true }, "familyName" : "Dora", "givenName" : "David", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 106568191, "link" : "/api/authorship/106568191", "label" : "Bokhari, Syeda Mahak Zahra [Bokhari, Syeda Mahak Zahra (Orvosi tudományok), szerző] Transzlációs Medicina Intézet (SE / AOK / I)", "listPosition" : 2, "share" : 0.125, "first" : false, "last" : false, "corresponding" : false, "author" : { "otype" : "Author", "mtid" : 10076178, "link" : "/api/author/10076178", "label" : "Bokhari Syeda Mahak Zahra (Orvosi tudományok)", "familyName" : "Bokhari", "givenName" : "Syeda Mahak Zahra", "published" : true, "snippet" : true }, "familyName" : "Bokhari", "givenName" : "Syeda Mahak Zahra", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 106568192, "link" : "/api/authorship/106568192", "label" : "Aloss, Kenan [Aloss, Kenan (Orvosi tudományok), szerző] Transzlációs Medicina Intézet (SE / AOK / I)", "listPosition" : 3, "share" : 0.125, "first" : false, "last" : false, "corresponding" : false, "author" : { "otype" : "Author", "mtid" : 10076182, "link" : "/api/author/10076182", "label" : "Aloss Kenan (Orvosi tudományok)", "familyName" : "Aloss", "givenName" : "Kenan", "published" : true, "snippet" : true }, "familyName" : "Aloss", "givenName" : "Kenan", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 106568193, "link" : "/api/authorship/106568193", "label" : "Takacs, Peter", "listPosition" : 4, "share" : 0.125, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Takacs", "givenName" : "Peter", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 106568194, "link" : "/api/authorship/106568194", "label" : "Desnoix, Juliane Zsuzsanna", "listPosition" : 5, "share" : 0.125, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Desnoix", "givenName" : "Juliane Zsuzsanna", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 106568195, "link" : "/api/authorship/106568195", "label" : "Szklenárik, György", "listPosition" : 6, "share" : 0.125, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Szklenárik", "givenName" : "György", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 106568196, "link" : "/api/authorship/106568196", "label" : "Hurley, Patrick Deniz", "listPosition" : 7, "share" : 0.125, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Hurley", "givenName" : "Patrick Deniz", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 106568197, "link" : "/api/authorship/106568197", "label" : "Lohinai, Zoltan ✉ [Lohinai, Zoltán (Onkológia), szerző] Transzlációs Medicina Intézet (SE / AOK / I)", "listPosition" : 8, "share" : 0.125, "first" : false, "last" : true, "corresponding" : true, "author" : { "otype" : "Author", "mtid" : 10044743, "link" : "/api/author/10044743", "label" : "Lohinai Zoltán (Onkológia)", "familyName" : "Lohinai", "givenName" : "Zoltán", "published" : true, "oldId" : 10044743, "snippet" : true }, "familyName" : "Lohinai", "givenName" : "Zoltan", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 22997256, "link" : "/api/publicationidentifier/22997256", "label" : "DOI: 10.3390/ijms24032769", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "oaType" : "GOLD", "oaFree" : true, "validState" : "IDENTICAL", "idValue" : "10.3390/ijms24032769", "realUrl" : "https://doi.org/10.3390/ijms24032769", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 23243778, "link" : "/api/publicationidentifier/23243778", "label" : "WoS: 000932795200001", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000932795200001", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/000932795200001", "published" : true, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 23100186, "link" : "/api/publicationidentifier/23100186", "label" : "Scopus: 85147893542", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85147893542", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85147893542", "published" : true, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 23066903, "link" : "/api/publicationidentifier/23066903", "label" : "PubMed: 36769093", "source" : { "otype" : "PlainSource", "mtid" : 17, "link" : "/api/publicationsource/17", "label" : "PubMed", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "PubMed", "nameEng" : "PubMed", "linkPattern" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract", "publiclyVisible" : true, "published" : true, "oldId" : 17, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "36769093", "realUrl" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36769093&dopt=Abstract", "published" : true, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 10003252, "link" : "/api/journal/10003252", "label" : "INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067", "pIssn" : "1661-6596", "eIssn" : "1422-0067", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 10003252, "snippet" : true }, "volume" : "24", "issue" : "3", "internalId" : "2769", "firstPageOrInternalIdForSort" : "2769", "pageLength" : 26, "publishedYear" : 2023, "abstractText" : "Immune checkpoint inhibitors (ICIs) have changed how we think about tumor management. Combinations of anti-programmed death ligand-1 (PD-L1) immunotherapy have become the standard of care in many advanced-stage cancers, including as a first-line therapy. Aside from improved anti-tumor immunity, the mechanism of action of immune checkpoint inhibitors (ICIs) exposes a new toxicity profile known as immune-related adverse effects (irAEs). This novel toxicity can damage any organ, but the skin, digestive and endocrine systems are the most frequently afflicted. Most ICI-attributed toxicity symptoms are mild, but some are severe and necessitate multidisciplinary side effect management. Obtaining knowledge on the various forms of immune-related toxicities and swiftly changing treatment techniques to lower the probability of experiencing severe irAEs has become a priority in oncological care. In recent years, there has been a growing understanding of an intriguing link between the gut microbiome and ICI outcomes. Multiple studies have demonstrated a connection between microbial metagenomic and metatranscriptomic patterns and ICI efficacy in malignant melanoma, lung and colorectal cancer. The immunomodulatory effect of the gut microbiome can have a real effect on the biological background of irAEs as well. Furthermore, specific microbial signatures and metabolites might be associated with the onset and severity of toxicity symptoms. By identifying these biological factors, novel biomarkers can be used in clinical practice to predict and manage potential irAEs. This comprehensive review aims to summarize the clinical aspects and biological background of ICI-related irAEs and their potential association with the gut microbiome and metabolome. We aim to explore the current state of knowledge on the most important and reliable irAE-related biomarkers of microbial origin and discuss the intriguing connection between ICI efficacy and toxicity.", "fundings" : [ { "otype" : "Funding", "mtid" : 2023162, "link" : "/api/funding/2023162", "label" : "(124652) Támogató: OTKA", "published" : false, "snippet" : true }, { "otype" : "Funding", "mtid" : 2023163, "link" : "/api/funding/2023163", "label" : "(129664) Támogató: OTKA", "published" : false, "snippet" : true }, { "otype" : "Funding", "mtid" : 2023164, "link" : "/api/funding/2023164", "label" : "(142287)", "published" : false, "snippet" : true }, { "otype" : "Funding", "mtid" : 2023165, "link" : "/api/funding/2023165", "label" : "(UNKP-22-5)", "published" : false, "snippet" : true }, { "otype" : "Funding", "mtid" : 2023166, "link" : "/api/funding/2023166", "label" : "(Bolyai Research Fellowship of the Hungarian Academy of Sciences)", "published" : false, "snippet" : true } ], "digital" : true, "printed" : null, "sourceYear" : 2023, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : true, "missingAuthor" : false, "oaType" : "GOLD", "oaCheckDate" : "2024-03-08", "oaFree" : true, "oaLink" : "https://doi.org/10.3390/ijms24032769", "citationCount" : 7, "citationCountUnpublished" : 0, "citationCountWoOther" : 7, "independentCitCountWoOther" : 7, "nationalOriginCitationCount" : 0, "foreignEditionCitationCount" : 7, "doiCitationCount" : 7, "wosCitationCount" : 6, "scopusCitationCount" : 2, "wosScopusCitationCount" : 6, "wosScopusCitationCountWoOther" : 6, "wosScopusIndependentCitationCount" : 6, "wosScopusIndependentCitationCountWoOther" : 6, "independentCitationCount" : 7, "selfCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 7, "independentCitingPubCount" : 7, "citingPubCountWoOther" : 7, "independentCitingPubCountWoOther" : 7, "unhandledCitingPubCount" : 0, "citedPubCount" : 3, "citedCount" : 3, "pubStats" : { "types" : [ { "type" : "Folyóiratcikk", "typeEng" : "Journal Article", "code" : 24, "count" : 7 }, { "type" : "Könyvrészlet", "typeEng" : "Chapter in Book", "code" : 25, "count" : 0 }, { "type" : "Könyv", "typeEng" : "Book", "code" : 23, "count" : 0 }, { "type" : "Egyéb konferenciaközlemény", "typeEng" : "Conference paper", "code" : 31, "count" : 0 }, { "type" : "Egyéb konferenciakötet", "typeEng" : "Conference proceedings", "code" : 32, "count" : 0 }, { "type" : "Oltalmi formák", "typeEng" : "Protection forms", "code" : 26, "count" : 0 }, { "type" : "Disszertáció", "typeEng" : "Thesis", "code" : 28, "count" : 0 }, { "type" : "Egyéb", "typeEng" : "Miscellaneous", "code" : 29, "count" : 0 }, { "type" : "Alkotás", "typeEng" : "Achievement", "code" : 22, "count" : 0 }, { "type" : "Kutatási adat", "typeEng" : "Research data", "code" : 33, "count" : 0 } ], "citationTypes" : [ { "type" : "Folyóiratcikk", "typeEng" : "Journal Article", "code" : 24, "countUnknown" : 0, "countIndependent" : 0, "countSelfCitation" : 0 }, { "type" : "Könyvrészlet", "typeEng" : "Chapter in Book", "code" : 25, "countUnknown" : 0, "countIndependent" : 0, "countSelfCitation" : 0 }, { "type" : "Könyv", "typeEng" : "Book", "code" : 23, "countUnknown" : 0, "countIndependent" : 0, "countSelfCitation" : 0 }, { "type" : "Egyéb konferenciaközlemény", "typeEng" : "Conference paper", "code" : 31, "countUnknown" : 0, "countIndependent" : 0, "countSelfCitation" : 0 }, { "type" : "Egyéb konferenciakötet", "typeEng" : "Conference proceedings", "code" : 32, "countUnknown" : 0, "countIndependent" : 0, "countSelfCitation" : 0 }, { "type" : "Oltalmi formák", "typeEng" : "Protection forms", "code" : 26, "countUnknown" : 0, "countIndependent" : 0, "countSelfCitation" : 0 }, { "type" : "Disszertáció", "typeEng" : "Thesis", "code" : 28, "countUnknown" : 0, "countIndependent" : 0, "countSelfCitation" : 0 }, { "type" : "Egyéb", "typeEng" : "Miscellaneous", "code" : 29, "countUnknown" : 0, "countIndependent" : 0, "countSelfCitation" : 0 }, { "type" : "Alkotás", "typeEng" : "Achievement", "code" : 22, "countUnknown" : 0, "countIndependent" : 0, "countSelfCitation" : 0 }, { "type" : "Kutatási adat", "typeEng" : "Research data", "code" : 33, "countUnknown" : 0, "countIndependent" : 0, "countSelfCitation" : 0 } ], "years" : [ { "year" : 2023, "publicationCount" : 0, "citationCount" : 6, "independentCitationCount" : 6, "citingPubCount" : 6, "independentCitingPubCount" : 6, "oaStats" : null, "oaStats2" : null }, { "year" : 2024, "publicationCount" : 0, "citationCount" : 1, "independentCitationCount" : 1, "citingPubCount" : 1, "independentCitingPubCount" : 1, "oaStats" : null, "oaStats2" : null } ] }, "ratings" : [ { "otype" : "SjrRating", "mtid" : 11388418, "link" : "/api/sjrrating/11388418", "label" : "sjr:D1 (2023) Scopus - Inorganic Chemistry INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067", "listPos" : 7, "rankValue" : 0.1, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 1604, "link" : "/api/classificationexternal/1604", "label" : "Scopus - Inorganic Chemistry", "published" : true, "oldId" : 1604, "snippet" : true }, "ranking" : "D1", "calculation" : "FROM_LAST_YEAR", "published" : true, "snippet" : true } ], "ratingsForSort" : "D1", "references" : [ { "otype" : "Reference", "mtid" : 38050636, "link" : "/api/reference/38050636", "label" : "1. Ai 2020: Research status and outlook of pd-1/pd-l1 inhibitors for cancer therapy., Drug Des. Dev. Ther., 14, p. 3625, DOI: 10.2147/DDDT.S267433", "listPosition" : 1, "doi" : "10.2147/DDDT.S267433", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050637, "link" : "/api/reference/38050637", "label" : "2. Bagchi 2021: Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance., Annu. Rev. Pathol. Mech. Dis., 16, p. 223, DOI: 10.1146/annurev-pathol-042020-042741", "listPosition" : 2, "doi" : "10.1146/annurev-pathol-042020-042741", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050638, "link" : "/api/reference/38050638", "label" : "3. Wardill 2022: Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: Supportive care implications and recommendations., Support Care Cancer, 30, p. 6369, DOI: 10.1007/s00520-022-06948-0", "listPosition" : 3, "doi" : "10.1007/s00520-022-06948-0", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050639, "link" : "/api/reference/38050639", "label" : "4. Lee 2010: Has the microbiota played a critical role in the evolution of the adaptive immune system?., Science, 330, p. 1768, DOI: 10.1126/science.1195568", "listPosition" : 4, "doi" : "10.1126/science.1195568", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050640, "link" : "/api/reference/38050640", "label" : "5. Pierrard 2019: Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review., Curr. Oncol., 26, p. 395, DOI: 10.3747/co.26.5177", "listPosition" : 5, "doi" : "10.3747/co.26.5177", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050641, "link" : "/api/reference/38050641", "label" : "6. Huang 2021: Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review., Front. Oncol., 11, p. 642110, DOI: 10.3389/fonc.2021.642110", "listPosition" : 6, "doi" : "10.3389/fonc.2021.642110", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050642, "link" : "/api/reference/38050642", "label" : "7. Gopalakrishnan 2018: Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients., Science, 359, p. 97, DOI: 10.1126/science.aan4236", "listPosition" : 7, "doi" : "10.1126/science.aan4236", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050643, "link" : "/api/reference/38050643", "label" : "8. Matson 2018: The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients., Science, 359, p. 104, DOI: 10.1126/science.aao3290", "listPosition" : 8, "doi" : "10.1126/science.aao3290", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050644, "link" : "/api/reference/38050644", "label" : "9. Limeta, A., Ji, B., Levin, M., Gatto, F., and Nielsen, J. (2020). Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. JCI Insight, 5., DOI: 10.1172/jci.insight.140940", "listPosition" : 9, "doi" : "10.1172/jci.insight.140940", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050645, "link" : "/api/reference/38050645", "label" : "10. Tobin 2014: Regulation of Intestinal Immune Responses through TLR Activation: Implications for Pro- and Prebiotics., Front Immunol., 5, p. 60", "listPosition" : 10, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050646, "link" : "/api/reference/38050646", "label" : "11. Zitvogel 2016: Microbiome and Anticancer Immunosurveillance., Cell, 165, p. 276, DOI: 10.1016/j.cell.2016.03.001", "listPosition" : 11, "doi" : "10.1016/j.cell.2016.03.001", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050647, "link" : "/api/reference/38050647", "label" : "12. Maillet 2019: A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors., Int. J. Cancer, 145, p. 639, DOI: 10.1002/ijc.32132", "listPosition" : 12, "doi" : "10.1002/ijc.32132", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050648, "link" : "/api/reference/38050648", "label" : "13. Martins 2019: Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance., Nat. Rev. Clin. Oncol., 16, p. 563, DOI: 10.1038/s41571-019-0218-0", "listPosition" : 13, "doi" : "10.1038/s41571-019-0218-0", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050649, "link" : "/api/reference/38050649", "label" : "14. Brown 2021: Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis., Cancer Investig., 39, p. 789, DOI: 10.1080/07357907.2021.1913502", "listPosition" : 14, "doi" : "10.1080/07357907.2021.1913502", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050650, "link" : "/api/reference/38050650", "label" : "15. Ouyang 2021: Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review., Front. Oncol., 11, p. 621639, DOI: 10.3389/fonc.2021.621639", "listPosition" : 15, "doi" : "10.3389/fonc.2021.621639", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050651, "link" : "/api/reference/38050651", "label" : "16. Okiyama 2022: Immune-related adverse events in various organs caused by immune checkpoint inhibitors., Allergol. Int., 71, p. 169, DOI: 10.1016/j.alit.2022.01.001", "listPosition" : 16, "doi" : "10.1016/j.alit.2022.01.001", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050652, "link" : "/api/reference/38050652", "label" : "17. Bardoscia 2021: Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation., Front. Pharmacol., 12, p. 746853, DOI: 10.3389/fphar.2021.746853", "listPosition" : 17, "doi" : "10.3389/fphar.2021.746853", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050653, "link" : "/api/reference/38050653", "label" : "18. Khan 2019: Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review., Semin. Cancer Biol., 64, p. 93, DOI: 10.1016/j.semcancer.2019.06.012", "listPosition" : 18, "doi" : "10.1016/j.semcancer.2019.06.012", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050654, "link" : "/api/reference/38050654", "label" : "19. Wang 2018: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis., JAMA Oncol., 4, p. 1721, DOI: 10.1001/jamaoncol.2018.3923", "listPosition" : 19, "doi" : "10.1001/jamaoncol.2018.3923", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050655, "link" : "/api/reference/38050655", "label" : "20. Conroy 2022: Immune-related adverse events and the balancing act of immunotherapy., Nat. Commun., 13, p. 1, DOI: 10.1038/s41467-022-27960-2", "listPosition" : 20, "doi" : "10.1038/s41467-022-27960-2", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050656, "link" : "/api/reference/38050656", "label" : "21. Esfahani 2019: Adverse events associated with immune checkpoint inhibitor treatment for cancer., Can. Med Assoc. J., 191, p. E40, DOI: 10.1503/cmaj.180870", "listPosition" : 21, "doi" : "10.1503/cmaj.180870", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050657, "link" : "/api/reference/38050657", "label" : "22. Postow 2018: Immune-Related Adverse Events Associated with Immune Checkpoint Blockade., N. Engl. J. Med., 378, p. 158, DOI: 10.1056/NEJMra1703481", "listPosition" : 22, "doi" : "10.1056/NEJMra1703481", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050658, "link" : "/api/reference/38050658", "label" : "23. Brahmer 2020: Immune-related adverse events of checkpoint inhibitors., Nat. Rev. Dis. Prim., 6, p. 1", "listPosition" : 23, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050659, "link" : "/api/reference/38050659", "label" : "24. Davar 2019: PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade., JAMA Oncol., 5, p. 942, DOI: 10.1001/jamaoncol.2019.0413", "listPosition" : 24, "doi" : "10.1001/jamaoncol.2019.0413", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050660, "link" : "/api/reference/38050660", "label" : "25. Wang 2019: Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis., JAMA Oncol., 5, p. 1008, DOI: 10.1001/jamaoncol.2019.0393", "listPosition" : 25, "doi" : "10.1001/jamaoncol.2019.0393", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050661, "link" : "/api/reference/38050661", "label" : "26. Wongvibulsin 2021: Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis., J. Am. Acad. Dermatol., 86, p. 563, DOI: 10.1016/j.jaad.2021.03.094", "listPosition" : 26, "doi" : "10.1016/j.jaad.2021.03.094", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050662, "link" : "/api/reference/38050662", "label" : "27. Zhao 2022: Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: A systematic review and meta-analysis., Sci. Rep., 12, p. 20038, DOI: 10.1038/s41598-022-24286-3", "listPosition" : 27, "doi" : "10.1038/s41598-022-24286-3", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050663, "link" : "/api/reference/38050663", "label" : "28. Phillips 2019: Treatment Outcomes of Immune-Related Cutaneous Adverse Events., J. Clin. Oncol., 37, p. 2746, DOI: 10.1200/JCO.18.02141", "listPosition" : 28, "doi" : "10.1200/JCO.18.02141", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050664, "link" : "/api/reference/38050664", "label" : "29. Chadha 2020: Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist., Curr. Dermatol. Rep., 9, p. 231, DOI: 10.1007/s13671-020-00314-1", "listPosition" : 29, "doi" : "10.1007/s13671-020-00314-1", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050665, "link" : "/api/reference/38050665", "label" : "30. Tang 2021: Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management., Front. Immunol., 12, p. 800879, DOI: 10.3389/fimmu.2021.800879", "listPosition" : 30, "doi" : "10.3389/fimmu.2021.800879", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050666, "link" : "/api/reference/38050666", "label" : "31. Antoni 2019: Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors., Eur. J. Cancer, 106, p. 106, DOI: 10.1016/j.ejca.2018.10.006", "listPosition" : 31, "doi" : "10.1016/j.ejca.2018.10.006", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050667, "link" : "/api/reference/38050667", "label" : "32. Shivaji 2019: Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management., Ther. Adv. Gastroenterol., 12, p. 1756284819884196, DOI: 10.1177/1756284819884196", "listPosition" : 32, "doi" : "10.1177/1756284819884196", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050668, "link" : "/api/reference/38050668", "label" : "33. Som 2019: Immune checkpoint inhibitor-induced colitis: A comprehensive review., World J. Clin. Cases, 7, p. 405, DOI: 10.12998/wjcc.v7.i4.405", "listPosition" : 33, "doi" : "10.12998/wjcc.v7.i4.405", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050669, "link" : "/api/reference/38050669", "label" : "34. Das 2019: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors., J. Immunother. Cancer, 7, p. 306, DOI: 10.1186/s40425-019-0805-8", "listPosition" : 34, "doi" : "10.1186/s40425-019-0805-8", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050670, "link" : "/api/reference/38050670", "label" : "35. Naqash 2021: The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer., Ann. Transl. Med., 9, p. 1034, DOI: 10.21037/atm-20-6427", "listPosition" : 35, "doi" : "10.21037/atm-20-6427", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050671, "link" : "/api/reference/38050671", "label" : "36. Eigentler 2018: Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders., Cancer Immunol. Immunother., 67, p. 825, DOI: 10.1007/s00262-018-2134-z", "listPosition" : 36, "doi" : "10.1007/s00262-018-2134-z", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050672, "link" : "/api/reference/38050672", "label" : "37. Guo 2020: Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: Systematic review and meta-analysis., Eur. J. Clin. Pharmacol., 76, p. 1345, DOI: 10.1007/s00228-020-02903-2", "listPosition" : 37, "doi" : "10.1007/s00228-020-02903-2", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050673, "link" : "/api/reference/38050673", "label" : "38. Winer 2018: Identifying and managing the adverse effects of immune checkpoint blockade., J. Thorac. Dis., 10, p. S480, DOI: 10.21037/jtd.2018.01.111", "listPosition" : 38, "doi" : "10.21037/jtd.2018.01.111", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050674, "link" : "/api/reference/38050674", "label" : "39. Rogers 2020: Management of Acute Pancreatitis Associated With Checkpoint Inhibitors., J. Adv. Pract. Oncol., 11, p. 49", "listPosition" : 39, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050675, "link" : "/api/reference/38050675", "label" : "40. Kakuwa, T., Hashimoto, M., Izumi, A., Naka, G., Takeda, Y., and Sugiyama, H. (2020). Pembrolizumab-related pancreatitis with elevation of pancreatic tumour markers. Respirol. Case Rep., 8., DOI: 10.1002/rcr2.525", "listPosition" : 40, "doi" : "10.1002/rcr2.525", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050676, "link" : "/api/reference/38050676", "label" : "41. Tian 2020: The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients with Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis., Front. Oncol., 10, p. 261, DOI: 10.3389/fonc.2020.00261", "listPosition" : 41, "doi" : "10.3389/fonc.2020.00261", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050677, "link" : "/api/reference/38050677", "label" : "42. Yin 2022: Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism., Front. Immunol., 13, p. 830631, DOI: 10.3389/fimmu.2022.830631", "listPosition" : 42, "doi" : "10.3389/fimmu.2022.830631", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050678, "link" : "/api/reference/38050678", "label" : "43. Cho 2018: Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer., Lung Cancer, 125, p. 150, DOI: 10.1016/j.lungcan.2018.09.015", "listPosition" : 43, "doi" : "10.1016/j.lungcan.2018.09.015", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050679, "link" : "/api/reference/38050679", "label" : "44. Banavasi, H., Kim, S., Alkassis, S., Daoud, A., Laktineh, A., Nagasaka, M., Sukari, A., and Soubani, A.O. (2021). Immune checkpoint inhibitor-induced pneumonitis: Incidence, clinical characteristics, and outcomes. Hematol. Stem Cell Ther., DOI: 10.1016/j.hemonc.2021.09.005", "listPosition" : 44, "doi" : "10.1016/j.hemonc.2021.09.005", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050680, "link" : "/api/reference/38050680", "label" : "45. Tiu, B.C., Zubiri, L., Iheke, J., Pahalyants, V., Theodosakis, N., Ugwu-Dike, P., Seo, J., Tang, K., E Sise, M., and Sullivan, R. (2022). Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: A multi-institutional cohort study. J. Immunother. Cancer, 10., DOI: 10.1136/jitc-2022-004670", "listPosition" : 45, "doi" : "10.1136/jitc-2022-004670", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050681, "link" : "/api/reference/38050681", "label" : "46. Long 2021: Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment., J. Clin. Endocrinol. Metab., 106, p. e3704, DOI: 10.1210/clinem/dgab263", "listPosition" : 46, "doi" : "10.1210/clinem/dgab263", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050682, "link" : "/api/reference/38050682", "label" : "47. Bazzell 2018: Clinical Management of Pneumonitis in Patients Receiving Anti–PD-1/PD-L1 Therapy., J. Adv. Pract. Oncol., 9, p. 422", "listPosition" : 47, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050683, "link" : "/api/reference/38050683", "label" : "48. Yoon 2021: Characteristics of immune-related thyroid adverse events in patients treated with PD-1/PD-L1 inhibitors., Endocrinol. Metab., 36, p. 413, DOI: 10.3803/EnM.2020.906", "listPosition" : 48, "doi" : "10.3803/EnM.2020.906", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050684, "link" : "/api/reference/38050684", "label" : "49. Chang 2018: Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., Endocrine Reviews, Volume 40, p. 17, DOI: 10.1210/er.2018-00006", "listPosition" : 49, "doi" : "10.1210/er.2018-00006", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050685, "link" : "/api/reference/38050685", "label" : "50. Osorio 2017: Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer., Ann. Oncol., 28, p. 583, DOI: 10.1093/annonc/mdw640", "listPosition" : 50, "doi" : "10.1093/annonc/mdw640", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050686, "link" : "/api/reference/38050686", "label" : "51. Kotwal 2020: PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients., Thyroid, 30, p. 177, DOI: 10.1089/thy.2019.0250", "listPosition" : 51, "doi" : "10.1089/thy.2019.0250", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050687, "link" : "/api/reference/38050687", "label" : "52. Baek, H.-S., Jeong, C., Shin, K., Lee, J., Suh, H., Lim, D.-J., Kang, M.I., and Ha, J. (2022). Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. BMC Endocr. Disord., 22., DOI: 10.1186/s12902-022-01004-8", "listPosition" : 52, "doi" : "10.1186/s12902-022-01004-8", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050688, "link" : "/api/reference/38050688", "label" : "53. Iwama, S., De Remigis, A., Callahan, M.K., Slovin, S.F., Wolchok, J.D., and Caturegli, P. (2014). Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. Sci. Transl. Med., 6., DOI: 10.1126/scitranslmed.3008002", "listPosition" : 53, "doi" : "10.1126/scitranslmed.3008002", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050689, "link" : "/api/reference/38050689", "label" : "54. Robert 2014: CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire., Clin. Cancer Res., 20, p. 2424, DOI: 10.1158/1078-0432.CCR-13-2648", "listPosition" : 54, "doi" : "10.1158/1078-0432.CCR-13-2648", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050690, "link" : "/api/reference/38050690", "label" : "55. Weber 2017: Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma., N. Engl. J. Med., 377, p. 1824, DOI: 10.1056/NEJMoa1709030", "listPosition" : 55, "doi" : "10.1056/NEJMoa1709030", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050691, "link" : "/api/reference/38050691", "label" : "56. Barry 2018: Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens., JAMA Oncol., 4, p. 173, DOI: 10.1001/jamaoncol.2017.3064", "listPosition" : 56, "doi" : "10.1001/jamaoncol.2017.3064", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050692, "link" : "/api/reference/38050692", "label" : "57. Shoushtari 2018: Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma., JAMA Oncol., 4, p. 98, DOI: 10.1001/jamaoncol.2017.2391", "listPosition" : 57, "doi" : "10.1001/jamaoncol.2017.2391", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050693, "link" : "/api/reference/38050693", "label" : "58. Ferrari, S.M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M.R., Baldini, E., Ulisse, S., and Marone, G. (2019). Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. Int. J. Mol. Sci., 20., DOI: 10.3390/ijms20102560", "listPosition" : 58, "doi" : "10.3390/ijms20102560", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050694, "link" : "/api/reference/38050694", "label" : "59. Sullivan 2021: Immune-related toxicities of checkpoint inhibitors: Mechanisms and mitigation strategies., Nat. Rev. Drug Discov., 21, p. 495, DOI: 10.1038/s41573-021-00259-5", "listPosition" : 59, "doi" : "10.1038/s41573-021-00259-5", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050695, "link" : "/api/reference/38050695", "label" : "60. Johnson 2016: Fulminant Myocarditis with Combination Immune Checkpoint Blockade., New Engl. J. Med., 375, p. 1749, DOI: 10.1056/NEJMoa1609214", "listPosition" : 60, "doi" : "10.1056/NEJMoa1609214", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050696, "link" : "/api/reference/38050696", "label" : "61. Ganatra 2018: Immune Checkpoint Inhibitor-Associated Myocarditis., Oncol., 23, p. 879, DOI: 10.1634/theoncologist.2018-0130", "listPosition" : 61, "doi" : "10.1634/theoncologist.2018-0130", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050697, "link" : "/api/reference/38050697", "label" : "62. Makunts 2021: Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data., Sci. Rep., 11, p. 17324, DOI: 10.1038/s41598-021-96467-5", "listPosition" : 62, "doi" : "10.1038/s41598-021-96467-5", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050698, "link" : "/api/reference/38050698", "label" : "63. Matzen 2021: Immune checkpoint inhibitor-induced myocarditis in cancer patients: A case report and review of reported cases., Cardiooncology, 7, p. 27", "listPosition" : 63, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050699, "link" : "/api/reference/38050699", "label" : "64. Castillo 2022: A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety., Front. Cell Dev. Biol., 10, p. 851032, DOI: 10.3389/fcell.2022.851032", "listPosition" : 64, "doi" : "10.3389/fcell.2022.851032", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050700, "link" : "/api/reference/38050700", "label" : "65. Salem 2018: Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study., Lancet Oncol., 19, p. 1579, DOI: 10.1016/S1470-2045(18)30608-9", "listPosition" : 65, "doi" : "10.1016/S1470-2045(18)30608-9", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050701, "link" : "/api/reference/38050701", "label" : "66. Dong 2022: PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism., Front. Pharmacol., 13, p. 1082", "listPosition" : 66, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050702, "link" : "/api/reference/38050702", "label" : "67. Safi 2021: PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines., J. Adv. Res., 29, p. 45, DOI: 10.1016/j.jare.2020.09.006", "listPosition" : 67, "doi" : "10.1016/j.jare.2020.09.006", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050703, "link" : "/api/reference/38050703", "label" : "68. Varricchi 2018: Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue., Curr. Med. Chem., 25, p. 1327, DOI: 10.2174/0929867324666170407125017", "listPosition" : 68, "doi" : "10.2174/0929867324666170407125017", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050704, "link" : "/api/reference/38050704", "label" : "69. Angelopoulou 2020: Immune checkpoint inhibitor-induced musculoskeletal manifestations., Rheumatol. Int., 41, p. 33, DOI: 10.1007/s00296-020-04665-7", "listPosition" : 69, "doi" : "10.1007/s00296-020-04665-7", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050705, "link" : "/api/reference/38050705", "label" : "70. Chan 2022: Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives., J. Inflamm. Res., 15, p. 3105, DOI: 10.2147/JIR.S282600", "listPosition" : 70, "doi" : "10.2147/JIR.S282600", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050706, "link" : "/api/reference/38050706", "label" : "71. Cappelli 2017: Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature., Arthritis Care Res., 69, p. 1751, DOI: 10.1002/acr.23177", "listPosition" : 71, "doi" : "10.1002/acr.23177", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050707, "link" : "/api/reference/38050707", "label" : "72. Kao 2017: Neurological Complications Associated with Anti–Programmed Death 1 (PD-1) Antibodies., JAMA Neurol., 74, p. 1216, DOI: 10.1001/jamaneurol.2017.1912", "listPosition" : 72, "doi" : "10.1001/jamaneurol.2017.1912", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050708, "link" : "/api/reference/38050708", "label" : "73. Moreira 2019: Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors., Eur. J. Cancer, 106, p. 12, DOI: 10.1016/j.ejca.2018.09.033", "listPosition" : 73, "doi" : "10.1016/j.ejca.2018.09.033", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050709, "link" : "/api/reference/38050709", "label" : "74. Psimaras 2018: Neuromuscular complications of immune checkpoint inhibitors., La Presse Médicale, 47, p. e253, DOI: 10.1016/j.lpm.2018.10.009", "listPosition" : 74, "doi" : "10.1016/j.lpm.2018.10.009", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050710, "link" : "/api/reference/38050710", "label" : "75. Kao 2018: Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors., Curr. Neurol. Neurosci. Rep., 18, p. 63, DOI: 10.1007/s11910-018-0878-7", "listPosition" : 75, "doi" : "10.1007/s11910-018-0878-7", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050711, "link" : "/api/reference/38050711", "label" : "76. Guptill 2011: Anti-musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts., Muscle Nerve, 44, p. 36, DOI: 10.1002/mus.22006", "listPosition" : 76, "doi" : "10.1002/mus.22006", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050712, "link" : "/api/reference/38050712", "label" : "77. Gilhus 2016: Myasthenia gravis—Autoantibody characteristics and their implications for therapy., Nat. Rev. Neurol., 12, p. 259, DOI: 10.1038/nrneurol.2016.44", "listPosition" : 77, "doi" : "10.1038/nrneurol.2016.44", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050713, "link" : "/api/reference/38050713", "label" : "78. Wilgenhof 2011: Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient., Ann. Oncol., 22, p. 991, DOI: 10.1093/annonc/mdr028", "listPosition" : 78, "doi" : "10.1093/annonc/mdr028", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050714, "link" : "/api/reference/38050714", "label" : "79. Xu 2019: Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-Analysis., Neurologist, 24, p. 75, DOI: 10.1097/NRL.0000000000000230", "listPosition" : 79, "doi" : "10.1097/NRL.0000000000000230", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050715, "link" : "/api/reference/38050715", "label" : "80. Fan 2021: Association of Immune Related Adverse Events with Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis., Front. Oncol., 11, p. 633032, DOI: 10.3389/fonc.2021.633032", "listPosition" : 80, "doi" : "10.3389/fonc.2021.633032", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050716, "link" : "/api/reference/38050716", "label" : "81. Man 2018: Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis., Asia-Pacific J. Clin. Oncol., 14, p. 141, DOI: 10.1111/ajco.12838", "listPosition" : 81, "doi" : "10.1111/ajco.12838", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050717, "link" : "/api/reference/38050717", "label" : "82. Johansen 2019: Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies., Neurology, 92, p. 663, DOI: 10.1212/WNL.0000000000007235", "listPosition" : 82, "doi" : "10.1212/WNL.0000000000007235", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050718, "link" : "/api/reference/38050718", "label" : "83. Willison 2016: Guillain-Barré syndrome., Lancet, 388, p. 717, DOI: 10.1016/S0140-6736(16)00339-1", "listPosition" : 83, "doi" : "10.1016/S0140-6736(16)00339-1", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050719, "link" : "/api/reference/38050719", "label" : "84. Larkin 2017: Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis., Oncology, 22, p. 709", "listPosition" : 84, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050720, "link" : "/api/reference/38050720", "label" : "85. Johnson 2019: Neurologic toxicity associated with immune checkpoint inhibitors: A pharmacovigilance study., J. Immunother. Cancer, 7, p. 134, DOI: 10.1186/s40425-019-0617-x", "listPosition" : 85, "doi" : "10.1186/s40425-019-0617-x", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050721, "link" : "/api/reference/38050721", "label" : "86. Narumi, Y., Yoshida, R., Minami, Y., Yamamoto, Y., Takeguchi, S., Kano, K., Takahashi, K., Saito, T., Sawada, J., and Terui, H. (2018). Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: The first report. BMC Cancer, 18., DOI: 10.1186/s12885-018-3997-2", "listPosition" : 86, "doi" : "10.1186/s12885-018-3997-2", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050722, "link" : "/api/reference/38050722", "label" : "87. Mancone 2018: Severe neurologic complications of immune checkpoint inhibitors: A single-center review., J. Neurol., 265, p. 1636, DOI: 10.1007/s00415-018-8890-z", "listPosition" : 87, "doi" : "10.1007/s00415-018-8890-z", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050723, "link" : "/api/reference/38050723", "label" : "88. Shimada 2019: Neuromyelitis optica spectrum disorder after treatment with pembrolizumab., Mult. Scler. Relat. Disord., 37, p. 101447, DOI: 10.1016/j.msard.2019.101447", "listPosition" : 88, "doi" : "10.1016/j.msard.2019.101447", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050724, "link" : "/api/reference/38050724", "label" : "89. Garcia 2019: Multiple sclerosis outcomes after cancer immunotherapy., Clin. Transl. Oncol., 21, p. 1336, DOI: 10.1007/s12094-019-02060-8", "listPosition" : 89, "doi" : "10.1007/s12094-019-02060-8", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050725, "link" : "/api/reference/38050725", "label" : "90. Hench 2017: Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade., J. Immunother. Cancer, 5, p. 46, DOI: 10.1186/s40425-017-0249-y", "listPosition" : 90, "doi" : "10.1186/s40425-017-0249-y", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050726, "link" : "/api/reference/38050726", "label" : "91. Bruno 2021: Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature., Front. Neurol., 12, p. 669493, DOI: 10.3389/fneur.2021.669493", "listPosition" : 91, "doi" : "10.3389/fneur.2021.669493", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050727, "link" : "/api/reference/38050727", "label" : "92. Watanabe 2019: Varicella zoster virus encephalitis mimicking nivolumab-induced autoimmune neuropathy in a patient with lung cancer., J. Thorac. Oncol., 14, p. e163, DOI: 10.1016/j.jtho.2019.02.033", "listPosition" : 92, "doi" : "10.1016/j.jtho.2019.02.033", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050728, "link" : "/api/reference/38050728", "label" : "93. Johnson 2019: A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis., Nat. Med., 25, p. 1243, DOI: 10.1038/s41591-019-0523-2", "listPosition" : 93, "doi" : "10.1038/s41591-019-0523-2", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050729, "link" : "/api/reference/38050729", "label" : "94. Sato 2019: Neurological and related adverse events in immune checkpoint inhibitors: A pharmacovigilance study from the Japanese Adverse Drug Event Report database., J. Neurooncol., 145, p. 1, DOI: 10.1007/s11060-019-03273-1", "listPosition" : 94, "doi" : "10.1007/s11060-019-03273-1", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050730, "link" : "/api/reference/38050730", "label" : "95. Owen 2021: Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma., Ann. Oncol., 32, p. 917, DOI: 10.1016/j.annonc.2021.03.204", "listPosition" : 95, "doi" : "10.1016/j.annonc.2021.03.204", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050731, "link" : "/api/reference/38050731", "label" : "96. Oh 2017: Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell RepertoireIpilimumab-Induced T-cell Diversity Predicts IRAEs., Cancer Res., 77, p. 1322, DOI: 10.1158/0008-5472.CAN-16-2324", "listPosition" : 96, "doi" : "10.1158/0008-5472.CAN-16-2324", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050732, "link" : "/api/reference/38050732", "label" : "97. Kumar 2019: Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis., Semin. Cancer Biol., 64, p. 29, DOI: 10.1016/j.semcancer.2019.01.006", "listPosition" : 97, "doi" : "10.1016/j.semcancer.2019.01.006", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050733, "link" : "/api/reference/38050733", "label" : "98. Denk 2022: Inflammation: The incubator of the tumor microenvironment., Trends Cancer, 8, p. 901, DOI: 10.1016/j.trecan.2022.07.002", "listPosition" : 98, "doi" : "10.1016/j.trecan.2022.07.002", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050734, "link" : "/api/reference/38050734", "label" : "99. Milling 2017: Delivering safer immunotherapies for cancer., Adv. Drug Deliv. Rev., 114, p. 79, DOI: 10.1016/j.addr.2017.05.011", "listPosition" : 99, "doi" : "10.1016/j.addr.2017.05.011", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050735, "link" : "/api/reference/38050735", "label" : "100. Yang 2020: Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation., Clin. Immunol., 213, p. 108377, DOI: 10.1016/j.clim.2020.108377", "listPosition" : 100, "doi" : "10.1016/j.clim.2020.108377", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050736, "link" : "/api/reference/38050736", "label" : "101. Zhou 2022: Mechanisms underlying immune-related adverse events during checkpoint immunotherapy., Clin. Sci., 136, p. 771, DOI: 10.1042/CS20210042", "listPosition" : 101, "doi" : "10.1042/CS20210042", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050737, "link" : "/api/reference/38050737", "label" : "102. Young 2018: The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy., Cancer Immunol. Res., 6, p. 1445, DOI: 10.1158/2326-6066.CIR-18-0487", "listPosition" : 102, "doi" : "10.1158/2326-6066.CIR-18-0487", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050738, "link" : "/api/reference/38050738", "label" : "103. Luoma 2020: Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy., Cell, 182, p. 655, DOI: 10.1016/j.cell.2020.06.001", "listPosition" : 103, "doi" : "10.1016/j.cell.2020.06.001", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050739, "link" : "/api/reference/38050739", "label" : "104. Kim 2020: Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment., Oncoimmunology, 9, p. 1722023, DOI: 10.1080/2162402X.2020.1722023", "listPosition" : 104, "doi" : "10.1080/2162402X.2020.1722023", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050740, "link" : "/api/reference/38050740", "label" : "105. Chodon 2009: CTLA4 blockade increases Th17 cells in patients with metastatic melanoma., J. Transl. Med., 7, p. 35, DOI: 10.1186/1479-5876-7-35", "listPosition" : 105, "doi" : "10.1186/1479-5876-7-35", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050741, "link" : "/api/reference/38050741", "label" : "106. Yoshino, K., Nakayama, T., Ito, A., Sato, E., and Kitano, S. (2019). Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: Potential role of Th1-dominant immune response in immune-related adverse events: Two case reports. BMC Cancer, 19., DOI: 10.1186/s12885-019-6138-7", "listPosition" : 106, "doi" : "10.1186/s12885-019-6138-7", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050742, "link" : "/api/reference/38050742", "label" : "107. Das 2018: Early B cell changes predict autoimmunity following combination immune checkpoint blockade., J. Clin. Investig., 128, p. 715, DOI: 10.1172/JCI96798", "listPosition" : 107, "doi" : "10.1172/JCI96798", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050743, "link" : "/api/reference/38050743", "label" : "108. Rozeman 2019: Autoantibody Development under Treatment with Immune-Checkpoint InhibitorsAutoantibodies under Immune-Checkpoint Inhibitors., Cancer Immunol. Res., 7, p. 6, DOI: 10.1158/2326-6066.CIR-18-0245", "listPosition" : 108, "doi" : "10.1158/2326-6066.CIR-18-0245", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050744, "link" : "/api/reference/38050744", "label" : "109. Esfahani 2020: Moving towards personalized treatments of immune-related adverse events., Nat. Rev. Clin. Oncol., 17, p. 504, DOI: 10.1038/s41571-020-0352-8", "listPosition" : 109, "doi" : "10.1038/s41571-020-0352-8", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050745, "link" : "/api/reference/38050745", "label" : "110. Stamatouli 2018: Collateral Damage: Insulin-Dependent Diabetes Induced with Checkpoint Inhibitors., Diabetes, 67, p. 1471, DOI: 10.2337/dbi18-0002", "listPosition" : 110, "doi" : "10.2337/dbi18-0002", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050746, "link" : "/api/reference/38050746", "label" : "111. Kolaczkowska 2013: Neutrophil recruitment and function in health and inflammation., Nat. Rev. Immunol., 13, p. 159, DOI: 10.1038/nri3399", "listPosition" : 111, "doi" : "10.1038/nri3399", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050747, "link" : "/api/reference/38050747", "label" : "112. Sibille 2019: Granulomatosis with polyangiitis in a patient on programmed death-1 inhibitor for advanced non-small-cell lung cancer., Front. Oncol., 9, p. 478, DOI: 10.3389/fonc.2019.00478", "listPosition" : 112, "doi" : "10.3389/fonc.2019.00478", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050748, "link" : "/api/reference/38050748", "label" : "113. Waldman 2020: A guide to cancer immunotherapy: From T cell basic science to clinical practice., Nat. Rev. Immunol., 20, p. 651, DOI: 10.1038/s41577-020-0306-5", "listPosition" : 113, "doi" : "10.1038/s41577-020-0306-5", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050749, "link" : "/api/reference/38050749", "label" : "114. Khan 2020: NK Cell-Based Immune Checkpoint Inhibition., Front. Immunol., 11, p. 167, DOI: 10.3389/fimmu.2020.00167", "listPosition" : 114, "doi" : "10.3389/fimmu.2020.00167", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050750, "link" : "/api/reference/38050750", "label" : "115. Jiang 2021: Highly activated TRAIL+ CD56bright NK cells are associated with the liver damage in HBV-LC patients., Immunol. Lett., 232, p. 9, DOI: 10.1016/j.imlet.2020.12.008", "listPosition" : 115, "doi" : "10.1016/j.imlet.2020.12.008", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050751, "link" : "/api/reference/38050751", "label" : "116. Milisenda 2019: Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern., Autoimmun. Rev., 19, p. 102455", "listPosition" : 116, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050752, "link" : "/api/reference/38050752", "label" : "117. Hu 2020: Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice., Proc. Natl. Acad. Sci. USA, 117, p. 31319, DOI: 10.1073/pnas.2019743117", "listPosition" : 117, "doi" : "10.1073/pnas.2019743117", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050753, "link" : "/api/reference/38050753", "label" : "118. Reinehr 2020: The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events., Immunobiology, 225, p. 152009, DOI: 10.1016/j.imbio.2020.152009", "listPosition" : 118, "doi" : "10.1016/j.imbio.2020.152009", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050754, "link" : "/api/reference/38050754", "label" : "119. Curry 2019: Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14 + and CD16 + monocytes driving an innate immune response., J. Cutan. Pathol., 46, p. 627, DOI: 10.1111/cup.13454", "listPosition" : 119, "doi" : "10.1111/cup.13454", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050755, "link" : "/api/reference/38050755", "label" : "120. Gudd 2021: Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis., J. Hepatol., 75, p. 177, DOI: 10.1016/j.jhep.2021.02.008", "listPosition" : 120, "doi" : "10.1016/j.jhep.2021.02.008", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050756, "link" : "/api/reference/38050756", "label" : "121. Soularue 2018: Enterocolitis due to immune checkpoint inhibitors: A systematic review., Gut, 67, p. 2056, DOI: 10.1136/gutjnl-2018-316948", "listPosition" : 121, "doi" : "10.1136/gutjnl-2018-316948", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050757, "link" : "/api/reference/38050757", "label" : "122. Le 2019: Gut microbiota: Implications for radiotherapy response and radiotherapy-induced mucositis., Expert Rev. Gastroenterol. Hepatol., 13, p. 485, DOI: 10.1080/17474124.2019.1595586", "listPosition" : 122, "doi" : "10.1080/17474124.2019.1595586", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050758, "link" : "/api/reference/38050758", "label" : "123. Chaput 2019: Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab., Ann. Oncol., 30, p. 2012, DOI: 10.1093/annonc/mdz224", "listPosition" : 123, "doi" : "10.1093/annonc/mdz224", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050759, "link" : "/api/reference/38050759", "label" : "124. Berg, M.-H.H., del Rincón, S.V., and Miller, W.H. (2022). Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: From monoclonal antibodies to kinase inhibition. J. Immunother. Cancer, 10., DOI: 10.1136/jitc-2021-003551", "listPosition" : 124, "doi" : "10.1136/jitc-2021-003551", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050760, "link" : "/api/reference/38050760", "label" : "125. Tan 2022: Gut microbiota shed new light on the management of immune-related adverse events., Thorac. Cancer, 13, p. 2681, DOI: 10.1111/1759-7714.14626", "listPosition" : 125, "doi" : "10.1111/1759-7714.14626", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050761, "link" : "/api/reference/38050761", "label" : "126. Andrews 2021: Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade., Nat. Med., 27, p. 1432, DOI: 10.1038/s41591-021-01406-6", "listPosition" : 126, "doi" : "10.1038/s41591-021-01406-6", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050762, "link" : "/api/reference/38050762", "label" : "127. Xu 2021: Inhibition of PD-1 Protects against TNBS-Induced Colitis via Alteration of Enteric Microbiota., BioMed Res. Int., 2021, p. 4192451", "listPosition" : 127, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050763, "link" : "/api/reference/38050763", "label" : "128. Davar 2022: Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy., Clin. Cancer Res., 28, p. 4370, DOI: 10.1158/1078-0432.CCR-21-1129", "listPosition" : 128, "doi" : "10.1158/1078-0432.CCR-21-1129", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050764, "link" : "/api/reference/38050764", "label" : "129. Hayase 2021: Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer., Genome Med., 13, p. 107, DOI: 10.1186/s13073-021-00923-w", "listPosition" : 129, "doi" : "10.1186/s13073-021-00923-w", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050765, "link" : "/api/reference/38050765", "label" : "130. Routy 2018: Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors., Science, 359, p. 91, DOI: 10.1126/science.aan3706", "listPosition" : 130, "doi" : "10.1126/science.aan3706", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050766, "link" : "/api/reference/38050766", "label" : "131. Seo 2015: Distinct Commensals Induce Interleukin-1beta via NLRP3 Inflammasome in Inflammatory Monocytes to Promote Intestinal Inflammation in Response to Injury., Immunity, 42, p. 744, DOI: 10.1016/j.immuni.2015.03.004", "listPosition" : 131, "doi" : "10.1016/j.immuni.2015.03.004", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050767, "link" : "/api/reference/38050767", "label" : "132. Lu 2022: Gut microbiota influence immunotherapy responses: Mechanisms and therapeutic strategies., J. Hematol. Oncol., 15, p. 47, DOI: 10.1186/s13045-022-01273-9", "listPosition" : 132, "doi" : "10.1186/s13045-022-01273-9", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050768, "link" : "/api/reference/38050768", "label" : "133. McCulloch 2022: Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1., Nat. Med., 28, p. 545, DOI: 10.1038/s41591-022-01698-2", "listPosition" : 133, "doi" : "10.1038/s41591-022-01698-2", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050769, "link" : "/api/reference/38050769", "label" : "134. Naqash 2020: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: A pooled exploratory analysis from a global cohort., Cancer Immunol. Immunother., 69, p. 1177, DOI: 10.1007/s00262-020-02536-5", "listPosition" : 134, "doi" : "10.1007/s00262-020-02536-5", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050770, "link" : "/api/reference/38050770", "label" : "135. Verzoni 2019: Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program., J. Immunother. Cancer, 7, p. 99, DOI: 10.1186/s40425-019-0579-z", "listPosition" : 135, "doi" : "10.1186/s40425-019-0579-z", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050771, "link" : "/api/reference/38050771", "label" : "136. Littmann 2021: Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection., Nat. Commun., 12, p. 755, DOI: 10.1038/s41467-020-20793-x", "listPosition" : 136, "doi" : "10.1038/s41467-020-20793-x", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050772, "link" : "/api/reference/38050772", "label" : "137. Baruch 2020: Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients., Science, 371, p. 602, DOI: 10.1126/science.abb5920", "listPosition" : 137, "doi" : "10.1126/science.abb5920", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050773, "link" : "/api/reference/38050773", "label" : "138. Davar 2021: Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients., Science, 371, p. 595, DOI: 10.1126/science.abf3363", "listPosition" : 138, "doi" : "10.1126/science.abf3363", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050774, "link" : "/api/reference/38050774", "label" : "139. Bernardes 2020: Fungal Infections Associated with the Use of Novel Immunotherapeutic Agents., Curr. Clin. Microbiol. Rep., 7, p. 142, DOI: 10.1007/s40588-020-00154-4", "listPosition" : 139, "doi" : "10.1007/s40588-020-00154-4", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050775, "link" : "/api/reference/38050775", "label" : "140. Zhang 2021: Bacteriophage-mediated modulation of microbiota for diseases treatment., Adv. Drug Deliv. Rev., 176, p. 113856, DOI: 10.1016/j.addr.2021.113856", "listPosition" : 140, "doi" : "10.1016/j.addr.2021.113856", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050776, "link" : "/api/reference/38050776", "label" : "141. Sakai 2021: Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis., Front. Oncol., 11, p. 763468, DOI: 10.3389/fonc.2021.763468", "listPosition" : 141, "doi" : "10.3389/fonc.2021.763468", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050777, "link" : "/api/reference/38050777", "label" : "142. Cascone 2021: Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial., Nat. Med., 27, p. 504, DOI: 10.1038/s41591-020-01224-2", "listPosition" : 142, "doi" : "10.1038/s41591-020-01224-2", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050778, "link" : "/api/reference/38050778", "label" : "143. Chau, J., Yadav, M., Liu, B., Furqan, M., Dai, Q., Shahi, S., Gupta, A., Mercer, K.N., Eastman, E., and Hejleh, T.A. (2021). Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer, 21., DOI: 10.1186/s12885-021-08530-z", "listPosition" : 143, "doi" : "10.1186/s12885-021-08530-z", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050779, "link" : "/api/reference/38050779", "label" : "144. Wang 2020: The effect of intestinal flora on immune checkpoint inhibitors in tumor treatment: A narrative review., Ann. Transl. Med., 8, p. 1097, DOI: 10.21037/atm-20-4535", "listPosition" : 144, "doi" : "10.21037/atm-20-4535", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050780, "link" : "/api/reference/38050780", "label" : "145. Bredin 2022: The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer., Cancer Metastasis Rev., 41, p. 347, DOI: 10.1007/s10555-022-10039-1", "listPosition" : 145, "doi" : "10.1007/s10555-022-10039-1", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050781, "link" : "/api/reference/38050781", "label" : "146. Dubin 2016: Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis., Nat. Commun., 7, p. 10391, DOI: 10.1038/ncomms10391", "listPosition" : 146, "doi" : "10.1038/ncomms10391", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050782, "link" : "/api/reference/38050782", "label" : "147. Kanjanapan 2020: Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy., Cancer Med., 9, p. 9027, DOI: 10.1002/cam4.3532", "listPosition" : 147, "doi" : "10.1002/cam4.3532", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050783, "link" : "/api/reference/38050783", "label" : "148. Liu 2021: Risk factors for immune-related adverse events: What have we learned and what lies ahead?., Biomark Res., 9, p. 79, DOI: 10.1186/s40364-021-00314-8", "listPosition" : 148, "doi" : "10.1186/s40364-021-00314-8", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050784, "link" : "/api/reference/38050784", "label" : "149. Lavelle 2020: Gut microbiota-derived metabolites as key actors in inflammatory bowel disease., Nat. Rev. Gastroenterol. Hepatol., 17, p. 223, DOI: 10.1038/s41575-019-0258-z", "listPosition" : 149, "doi" : "10.1038/s41575-019-0258-z", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050785, "link" : "/api/reference/38050785", "label" : "150. Lensu, S., and Pekkala, S. (2021). Gut Microbiota, Microbial Metabolites and Human Physical Performance. Metabolites, 11., DOI: 10.3390/metabo11110716", "listPosition" : 150, "doi" : "10.3390/metabo11110716", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050786, "link" : "/api/reference/38050786", "label" : "151. Zhai, L., Wu, J., Lam, Y.Y., Kwan, H.Y., Bian, Z.-X., and Wong, H.L.X. (2021). Gut-Microbial Metabolites, Probiotics and Their Roles in Type 2 Diabetes. Int. J. Mol. Sci., 22., DOI: 10.3390/ijms222312846", "listPosition" : 151, "doi" : "10.3390/ijms222312846", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050787, "link" : "/api/reference/38050787", "label" : "152. Vinolo 2011: Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils., J. Nutr. Biochem., 22, p. 849, DOI: 10.1016/j.jnutbio.2010.07.009", "listPosition" : 152, "doi" : "10.1016/j.jnutbio.2010.07.009", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050788, "link" : "/api/reference/38050788", "label" : "153. Kaiko 2016: The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites., Cell, 165, p. 1708, DOI: 10.1016/j.cell.2016.05.018", "listPosition" : 153, "doi" : "10.1016/j.cell.2016.05.018", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050789, "link" : "/api/reference/38050789", "label" : "154. Chen 2022: Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages., J. Exp. Clin. Cancer Res., 41, p. 1, DOI: 10.1186/s13046-021-02201-4", "listPosition" : 154, "doi" : "10.1186/s13046-021-02201-4", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050790, "link" : "/api/reference/38050790", "label" : "155. Simpson 2022: Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome., Nat. Med., 28, p. 2344, DOI: 10.1038/s41591-022-01965-2", "listPosition" : 155, "doi" : "10.1038/s41591-022-01965-2", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050791, "link" : "/api/reference/38050791", "label" : "156. Fellows 2018: Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases., Nat. Commun., 9, p. 105, DOI: 10.1038/s41467-017-02651-5", "listPosition" : 156, "doi" : "10.1038/s41467-017-02651-5", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050792, "link" : "/api/reference/38050792", "label" : "157. Tao 2007: Deacetylase inhibition promotes the generation and function of regulatory T cells., Nat. Med., 13, p. 1299, DOI: 10.1038/nm1652", "listPosition" : 157, "doi" : "10.1038/nm1652", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050793, "link" : "/api/reference/38050793", "label" : "158. Iraporda 2016: Local Treatment with Lactate Prevents Intestinal Inflammation in the TNBS-Induced Colitis Model., Front. Immunol., 7, p. 651, DOI: 10.3389/fimmu.2016.00651", "listPosition" : 158, "doi" : "10.3389/fimmu.2016.00651", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050794, "link" : "/api/reference/38050794", "label" : "159. Sun 2021: Lactic Acid-Producing Probiotic Saccharomyces cerevisiae Attenuates Ulcerative Colitis via Suppressing Macrophage Pyroptosis and Modulating Gut Microbiota., Front. Immunol., 12, p. 777665, DOI: 10.3389/fimmu.2021.777665", "listPosition" : 159, "doi" : "10.3389/fimmu.2021.777665", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050795, "link" : "/api/reference/38050795", "label" : "160. Wagner 2016: Lactate Stimulates IL-4 and IL-13 Production in Activated HuT-78 T Lymphocytes Through a Process That Involves Monocarboxylate Transporters and Protein Hyperacetylation., J. Interf. Cytokine Res., 36, p. 317, DOI: 10.1089/jir.2015.0086", "listPosition" : 160, "doi" : "10.1089/jir.2015.0086", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050796, "link" : "/api/reference/38050796", "label" : "161. Zhang 1997: Spermine Inhibits Proinflammatory Cytokine Synthesis in Human Mononuclear Cells: A Counterregulatory Mechanism that Restrains the Immune Response., J. Exp. Med., 185, p. 1759, DOI: 10.1084/jem.185.10.1759", "listPosition" : 161, "doi" : "10.1084/jem.185.10.1759", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050797, "link" : "/api/reference/38050797", "label" : "162. Renga, G., Nunzi, E., Pariano, M., Puccetti, M., Bellet, M.M., Pieraccini, G., D’Onofrio, F., Santarelli, I., Stincardini, C., and Aversa, F. (2022). Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite. J. Immunother. Cancer, 10., DOI: 10.1136/jitc-2021-003725", "listPosition" : 162, "doi" : "10.1136/jitc-2021-003725", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050798, "link" : "/api/reference/38050798", "label" : "163. Alexeev 2018: Microbiota-Derived Indole Metabolites Promote Human and Murine Intestinal Homeostasis through Regulation of Interleukin-10 Receptor., Am. J. Pathol., 188, p. 1183, DOI: 10.1016/j.ajpath.2018.01.011", "listPosition" : 163, "doi" : "10.1016/j.ajpath.2018.01.011", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050799, "link" : "/api/reference/38050799", "label" : "164. Wang 2022: The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer., Cell Metab., 34, p. 581, DOI: 10.1016/j.cmet.2022.02.010", "listPosition" : 164, "doi" : "10.1016/j.cmet.2022.02.010", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050800, "link" : "/api/reference/38050800", "label" : "165. Haghikia 2018: Gut Microbiota-Dependent Trimethylamine N-Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes., Arterioscler. Thromb. Vasc. Biol., 38, p. 2225, DOI: 10.1161/ATVBAHA.118.311023", "listPosition" : 165, "doi" : "10.1161/ATVBAHA.118.311023", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050801, "link" : "/api/reference/38050801", "label" : "166. Tang 2013: Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk., N. Engl. J. Med., 368, p. 1575, DOI: 10.1056/NEJMoa1109400", "listPosition" : 166, "doi" : "10.1056/NEJMoa1109400", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050802, "link" : "/api/reference/38050802", "label" : "167. Round 2011: The Toll-Like Receptor 2 Pathway Establishes Colonization by a Commensal of the Human Microbiota., Science, 332, p. 974, DOI: 10.1126/science.1206095", "listPosition" : 167, "doi" : "10.1126/science.1206095", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050803, "link" : "/api/reference/38050803", "label" : "168. Gunasekera 2020: The development of colitis in Il10 mice is dependent on IL-22., Mucosal Immunol., 13, p. 493, DOI: 10.1038/s41385-019-0252-3", "listPosition" : 168, "doi" : "10.1038/s41385-019-0252-3", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050804, "link" : "/api/reference/38050804", "label" : "169. Nomura, M., Nagatomo, R., Doi, K., Shimizu, J., Baba, K., Saito, T., Matsumoto, S., Inoue, K., and Muto, M. (2020). Association of Short-Chain Fatty Acids in the Gut Microbiome with Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors. JAMA Netw. Open, 3., DOI: 10.1001/jamanetworkopen.2020.2895", "listPosition" : 169, "doi" : "10.1001/jamanetworkopen.2020.2895", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050805, "link" : "/api/reference/38050805", "label" : "170. Botticelli 2020: Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment., J. Transl. Med., 18, p. 49, DOI: 10.1186/s12967-020-02231-0", "listPosition" : 170, "doi" : "10.1186/s12967-020-02231-0", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050806, "link" : "/api/reference/38050806", "label" : "171. Andriamihaja 2015: The deleterious metabolic and genotoxic effects of the bacterial metabolite p-cresol on colonic epithelial cells., Free. Radic. Biol. Med., 85, p. 219, DOI: 10.1016/j.freeradbiomed.2015.04.004", "listPosition" : 171, "doi" : "10.1016/j.freeradbiomed.2015.04.004", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050807, "link" : "/api/reference/38050807", "label" : "172. Coutzac 2020: Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer., Nat. Commun., 11, p. 2168, DOI: 10.1038/s41467-020-16079-x", "listPosition" : 172, "doi" : "10.1038/s41467-020-16079-x", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050808, "link" : "/api/reference/38050808", "label" : "173. Pan, Y., Liu, Y., Guo, H., Jabir, M.S., Liu, X., Cui, W., and Li, D. (2017). Associations between Folate and Vitamin B12 Levels and Inflammatory Bowel Disease: A Meta-Analysis. Nutrients, 9., DOI: 10.3390/nu9040382", "listPosition" : 173, "doi" : "10.3390/nu9040382", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050809, "link" : "/api/reference/38050809", "label" : "174. Peters 2019: Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients., Genome Med., 11, p. 61, DOI: 10.1186/s13073-019-0672-4", "listPosition" : 174, "doi" : "10.1186/s13073-019-0672-4", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050810, "link" : "/api/reference/38050810", "label" : "175. Frankel 2017: Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients., Neoplasia, 19, p. 848, DOI: 10.1016/j.neo.2017.08.004", "listPosition" : 175, "doi" : "10.1016/j.neo.2017.08.004", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050811, "link" : "/api/reference/38050811", "label" : "176. Mao, J., Wang, D., Long, J., Yang, X., Lin, J., Song, Y., Xie, F., Xun, Z., Wang, Y., and Wang, Y. (2021). Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J. Immunother. Cancer, 9., DOI: 10.1136/jitc-2021-003334", "listPosition" : 176, "doi" : "10.1136/jitc-2021-003334", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050812, "link" : "/api/reference/38050812", "label" : "177. Zheng 2019: Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma., J. Immunother. Cancer, 7, p. 193, DOI: 10.1186/s40425-019-0650-9", "listPosition" : 177, "doi" : "10.1186/s40425-019-0650-9", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050813, "link" : "/api/reference/38050813", "label" : "178. Wind 2020: Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma., Melanoma Res., 30, p. 235, DOI: 10.1097/CMR.0000000000000656", "listPosition" : 178, "doi" : "10.1097/CMR.0000000000000656", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050814, "link" : "/api/reference/38050814", "label" : "179. Johns 2021: Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer., J. Geriatr. Oncol., 12, p. 813, DOI: 10.1016/j.jgo.2021.02.002", "listPosition" : 179, "doi" : "10.1016/j.jgo.2021.02.002", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050815, "link" : "/api/reference/38050815", "label" : "180. Sato 2018: Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab., Lung Cancer, 115, p. 71, DOI: 10.1016/j.lungcan.2017.11.019", "listPosition" : 180, "doi" : "10.1016/j.lungcan.2017.11.019", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050816, "link" : "/api/reference/38050816", "label" : "181. Grangeon 2018: Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer., Clin. Lung Cancer, 20, p. 201, DOI: 10.1016/j.cllc.2018.10.002", "listPosition" : 181, "doi" : "10.1016/j.cllc.2018.10.002", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050817, "link" : "/api/reference/38050817", "label" : "182. Ricciuti 2018: Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: Long-term outcomes from a multi-institutional analysis., J. Cancer Res. Clin. Oncol., 145, p. 479, DOI: 10.1007/s00432-018-2805-3", "listPosition" : 182, "doi" : "10.1007/s00432-018-2805-3", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050818, "link" : "/api/reference/38050818", "label" : "183. Martini 2021: Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors., Oncol., 26, p. e1742, DOI: 10.1002/onco.13868", "listPosition" : 183, "doi" : "10.1002/onco.13868", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050819, "link" : "/api/reference/38050819", "label" : "184. Das 2020: Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy., Oncology, 25, p. 669", "listPosition" : 184, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050820, "link" : "/api/reference/38050820", "label" : "185. Masuda, K., Shoji, H., Nagashima, K., Yamamoto, S., Ishikawa, M., Imazeki, H., Aoki, M., Miyamoto, T., Hirano, H., and Honma, Y. (2019). Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer, 19., DOI: 10.1186/s12885-019-6150-y", "listPosition" : 185, "doi" : "10.1186/s12885-019-6150-y", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050821, "link" : "/api/reference/38050821", "label" : "186. Foster 2021: Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors., Cancer, 127, p. 4565, DOI: 10.1002/cncr.33780", "listPosition" : 186, "doi" : "10.1002/cncr.33780", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050822, "link" : "/api/reference/38050822", "label" : "187. Fan 2021: Guillain–Barré syndrome in patients treated with immune checkpoint inhibitors., J. Neurol., 268, p. 2169, DOI: 10.1007/s00415-021-10404-0", "listPosition" : 187, "doi" : "10.1007/s00415-021-10404-0", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050823, "link" : "/api/reference/38050823", "label" : "188. Teraoka 2017: Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study., J. Thorac. Oncol., 12, p. 1798, DOI: 10.1016/j.jtho.2017.08.022", "listPosition" : 188, "doi" : "10.1016/j.jtho.2017.08.022", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050824, "link" : "/api/reference/38050824", "label" : "189. Morehouse 2019: Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune-checkpoint inhibitors (ICIs)., J. Clin. Oncol., 37, p. 2563, DOI: 10.1200/JCO.2019.37.15_suppl.2563", "listPosition" : 189, "doi" : "10.1200/JCO.2019.37.15_suppl.2563", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050825, "link" : "/api/reference/38050825", "label" : "190. Faje 2018: High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma., Cancer, 124, p. 3706, DOI: 10.1002/cncr.31629", "listPosition" : 190, "doi" : "10.1002/cncr.31629", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050826, "link" : "/api/reference/38050826", "label" : "191. Arbour 2018: Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer., J. Clin. Oncol., 36, p. 2872, DOI: 10.1200/JCO.2018.79.0006", "listPosition" : 191, "doi" : "10.1200/JCO.2018.79.0006", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050827, "link" : "/api/reference/38050827", "label" : "192. Hodi 2014: Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial., JAMA, 312, p. 1744, DOI: 10.1001/jama.2014.13943", "listPosition" : 192, "doi" : "10.1001/jama.2014.13943", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050828, "link" : "/api/reference/38050828", "label" : "193. Hailemichael 2022: Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity., Cancer Cell, 40, p. 509, DOI: 10.1016/j.ccell.2022.04.004", "listPosition" : 193, "doi" : "10.1016/j.ccell.2022.04.004", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050829, "link" : "/api/reference/38050829", "label" : "194. Sender, R., Fuchs, S., and Milo, R. (2016). Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLOS Biol., 14., DOI: 10.1101/036103", "listPosition" : 194, "doi" : "10.1101/036103", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050830, "link" : "/api/reference/38050830", "label" : "195. Pitt 2015: Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota., Science, 350, p. 1079, DOI: 10.1126/science.aad1329", "listPosition" : 195, "doi" : "10.1126/science.aad1329", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050831, "link" : "/api/reference/38050831", "label" : "196. Sivan 2015: Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy., Science, 350, p. 1084, DOI: 10.1126/science.aac4255", "listPosition" : 196, "doi" : "10.1126/science.aac4255", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050832, "link" : "/api/reference/38050832", "label" : "197. Tanoue 2019: A defined commensal consortium elicits CD8 T cells and anti-cancer immunity., Nature, 565, p. 600, DOI: 10.1038/s41586-019-0878-z", "listPosition" : 197, "doi" : "10.1038/s41586-019-0878-z", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050833, "link" : "/api/reference/38050833", "label" : "198. Hua 2015: Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue., Nanomed. Nanotechnol. Biol. Med., 11, p. 1117, DOI: 10.1016/j.nano.2015.02.018", "listPosition" : 198, "doi" : "10.1016/j.nano.2015.02.018", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050834, "link" : "/api/reference/38050834", "label" : "199. Angsantikul 2018: Coating Nanoparticles with Gastric Epithelial Cell Membrane for Targeted Antibiotic Delivery against Helicobacter pylori Infection., Adv. Ther., 1, p. 1800016, DOI: 10.1002/adtp.201800016", "listPosition" : 199, "doi" : "10.1002/adtp.201800016", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050835, "link" : "/api/reference/38050835", "label" : "200. Jin 2017: Biomimetic nanoparticles for inflammation targeting., Acta Pharm. Sin. B, 8, p. 23, DOI: 10.1016/j.apsb.2017.12.002", "listPosition" : 200, "doi" : "10.1016/j.apsb.2017.12.002", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050836, "link" : "/api/reference/38050836", "label" : "201. Lai 2009: Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues., Adv. Drug Deliv. Rev., 61, p. 158, DOI: 10.1016/j.addr.2008.11.002", "listPosition" : 201, "doi" : "10.1016/j.addr.2008.11.002", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050837, "link" : "/api/reference/38050837", "label" : "202. Pridgen 2013: Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery., Sci. Transl. Med., 5, p. 213ra167, DOI: 10.1126/scitranslmed.3007049", "listPosition" : 202, "doi" : "10.1126/scitranslmed.3007049", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050838, "link" : "/api/reference/38050838", "label" : "203. Bullman 2017: Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer., Science, 358, p. 1443, DOI: 10.1126/science.aal5240", "listPosition" : 203, "doi" : "10.1126/science.aal5240", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050839, "link" : "/api/reference/38050839", "label" : "204. Riquelme 2019: Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes., Cell, 178, p. 795, DOI: 10.1016/j.cell.2019.07.008", "listPosition" : 204, "doi" : "10.1016/j.cell.2019.07.008", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050840, "link" : "/api/reference/38050840", "label" : "205. Brown 2004: Exploiting tumour hypoxia in cancer treatment., Nat. Rev. Cancer, 4, p. 437, DOI: 10.1038/nrc1367", "listPosition" : 205, "doi" : "10.1038/nrc1367", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050841, "link" : "/api/reference/38050841", "label" : "206. Poon 2011: Layer-by-Layer Nanoparticles with a pH-Sheddable Layer for in Vivo Targeting of Tumor Hypoxia., ACS Nano, 5, p. 4284, DOI: 10.1021/nn200876f", "listPosition" : 206, "doi" : "10.1021/nn200876f", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050842, "link" : "/api/reference/38050842", "label" : "207. Song 2018: Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap., Nat. Commun., 9, p. 2237, DOI: 10.1038/s41467-018-04605-x", "listPosition" : 207, "doi" : "10.1038/s41467-018-04605-x", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050843, "link" : "/api/reference/38050843", "label" : "208. Mimee 2016: Microbiome therapeutics—Advances and challenges., Adv. Drug Deliv. Rev., 105, p. 44, DOI: 10.1016/j.addr.2016.04.032", "listPosition" : 208, "doi" : "10.1016/j.addr.2016.04.032", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050844, "link" : "/api/reference/38050844", "label" : "209. Singh 2014: Activation of Gpr109a, Receptor for Niacin and the Commensal Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis., Immunity, 40, p. 128, DOI: 10.1016/j.immuni.2013.12.007", "listPosition" : 209, "doi" : "10.1016/j.immuni.2013.12.007", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050845, "link" : "/api/reference/38050845", "label" : "210. Wang 2011: Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers., ISME J., 6, p. 320, DOI: 10.1038/ismej.2011.109", "listPosition" : 210, "doi" : "10.1038/ismej.2011.109", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050846, "link" : "/api/reference/38050846", "label" : "211. Iida 2013: Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment., Science, 342, p. 967, DOI: 10.1126/science.1240527", "listPosition" : 211, "doi" : "10.1126/science.1240527", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050847, "link" : "/api/reference/38050847", "label" : "212. Vangay 2015: Antibiotics, Pediatric Dysbiosis, and Disease., Cell Host Microbe, 17, p. 553, DOI: 10.1016/j.chom.2015.04.006", "listPosition" : 212, "doi" : "10.1016/j.chom.2015.04.006", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050848, "link" : "/api/reference/38050848", "label" : "213. Francescone 2014: Microbiome, Inflammation, and Cancer., Cancer J., 20, p. 181, DOI: 10.1097/PPO.0000000000000048", "listPosition" : 213, "doi" : "10.1097/PPO.0000000000000048", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050849, "link" : "/api/reference/38050849", "label" : "214. Wu 2013: Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer Patients., Microb. Ecol., 66, p. 462, DOI: 10.1007/s00248-013-0245-9", "listPosition" : 214, "doi" : "10.1007/s00248-013-0245-9", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050850, "link" : "/api/reference/38050850", "label" : "215. Ramteke 2009: Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori., J. Drug Target., 17, p. 225, DOI: 10.1080/10611860902718649", "listPosition" : 215, "doi" : "10.1080/10611860902718649", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050851, "link" : "/api/reference/38050851", "label" : "216. Hajipour 2012: Antibacterial properties of nanoparticles., Trends Biotechnol., 30, p. 499, DOI: 10.1016/j.tibtech.2012.06.004", "listPosition" : 216, "doi" : "10.1016/j.tibtech.2012.06.004", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050852, "link" : "/api/reference/38050852", "label" : "217. Memarzadeh 2012: Antimicrobial activity of nanoparticulate metal oxides against peri-implantitis pathogens., Int. J. Antimicrob. Agents, 40, p. 135, DOI: 10.1016/j.ijantimicag.2012.04.012", "listPosition" : 217, "doi" : "10.1016/j.ijantimicag.2012.04.012", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050853, "link" : "/api/reference/38050853", "label" : "218. Lu 2013: Size-dependent antibacterial activities of silver nanoparticles against oral anaerobic pathogenic bacteria., J. Mater. Sci. Mater. Med., 24, p. 1465, DOI: 10.1007/s10856-013-4894-5", "listPosition" : 218, "doi" : "10.1007/s10856-013-4894-5", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050854, "link" : "/api/reference/38050854", "label" : "219. Gao 2014: Nanoparticle approaches against bacterial infections., WIREs Nanomed. Nanobiotechnology, 6, p. 532, DOI: 10.1002/wnan.1282", "listPosition" : 219, "doi" : "10.1002/wnan.1282", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050855, "link" : "/api/reference/38050855", "label" : "220. Anselmo 2016: Nanoparticles in the clinic., Bioeng. Transl. Med., 1, p. 10, DOI: 10.1002/btm2.10003", "listPosition" : 220, "doi" : "10.1002/btm2.10003", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050856, "link" : "/api/reference/38050856", "label" : "221. Citorik 2014: Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases., Nat. Biotechnol., 32, p. 1141, DOI: 10.1038/nbt.3011", "listPosition" : 221, "doi" : "10.1038/nbt.3011", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050857, "link" : "/api/reference/38050857", "label" : "222. Lam 2021: Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome., Cell Rep., 37, p. 109930, DOI: 10.1016/j.celrep.2021.109930", "listPosition" : 222, "doi" : "10.1016/j.celrep.2021.109930", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050858, "link" : "/api/reference/38050858", "label" : "223. Rodrigues, M., McBride, S.W., Hullahalli, K., Palmer, K.L., and Duerkop, B.A. (2019). Conjugative Delivery of CRISPR-Cas9 for the Selective Depletion of Antibiotic-Resistant Enterococci. Antimicrob. Agents Chemother., 63., DOI: 10.1128/AAC.01454-19", "listPosition" : 223, "doi" : "10.1128/AAC.01454-19", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050859, "link" : "/api/reference/38050859", "label" : "224. Neil 2021: High-efficiency delivery of CRISPR-Cas9 by engineered probiotics enables precise microbiome editing., Mol. Syst. Biol., 17, p. e10335, DOI: 10.15252/msb.202110335", "listPosition" : 224, "doi" : "10.15252/msb.202110335", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050860, "link" : "/api/reference/38050860", "label" : "225. Rogovski 2021: Uses of Bacteriophages as Bacterial Control Tools and Environmental Safety Indicators., Front. Microbiol., 12, p. 793135, DOI: 10.3389/fmicb.2021.793135", "listPosition" : 225, "doi" : "10.3389/fmicb.2021.793135", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050861, "link" : "/api/reference/38050861", "label" : "226. Veeranarayanan, S., Azam, A.H., Kiga, K., Watanabe, S., and Cui, L. (2021). Bacteriophages as Solid Tumor Theragnostic Agents. Int. J. Mol. Sci., 23., DOI: 10.3390/ijms23010402", "listPosition" : 226, "doi" : "10.3390/ijms23010402", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050862, "link" : "/api/reference/38050862", "label" : "227. Foglizzo, V., and Marchiò, S. (2021). Bacteriophages as Therapeutic and Diagnostic Vehicles in Cancer. Pharmaceuticals, 14., DOI: 10.3390/ph14020161", "listPosition" : 227, "doi" : "10.3390/ph14020161", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050863, "link" : "/api/reference/38050863", "label" : "228. Petrov, G., Dymova, M., and Richter, V. (2022). Bacteriophage-Mediated Cancer Gene Therapy. Int. J. Mol. Sci., 23., DOI: 10.3390/ijms232214245", "listPosition" : 228, "doi" : "10.3390/ijms232214245", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050864, "link" : "/api/reference/38050864", "label" : "229. Ghaderi, S.S., Riazi-Rad, F., Qamsari, E.S., Bagheri, S., Rahimi-Jamnani, F., and Sharifzadeh, Z. (2022). Development of a human phage display-derived anti-PD-1 scFv antibody: An attractive tool for immune checkpoint therapy. BMC Biotechnol., 22., DOI: 10.1186/s12896-022-00752-8", "listPosition" : 229, "doi" : "10.1186/s12896-022-00752-8", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050865, "link" : "/api/reference/38050865", "label" : "230. Fluckiger 2020: Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage., Science, 369, p. 936, DOI: 10.1126/science.aax0701", "listPosition" : 230, "doi" : "10.1126/science.aax0701", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050866, "link" : "/api/reference/38050866", "label" : "231. Wong 2021: Therapeutic interventions and mechanisms associated with gut microbiota-mediated modulation of immune checkpoint inhibitor responses., Microbes Infect., 23, p. 104804, DOI: 10.1016/j.micinf.2021.104804", "listPosition" : 231, "doi" : "10.1016/j.micinf.2021.104804", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050867, "link" : "/api/reference/38050867", "label" : "232. Araya 2010: Deletion of a prophage-like element causes attenuation of Salmonella enterica serovar Enteritidis and promotes protective immunity., Vaccine, 28, p. 5458, DOI: 10.1016/j.vaccine.2010.05.073", "listPosition" : 232, "doi" : "10.1016/j.vaccine.2010.05.073", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050868, "link" : "/api/reference/38050868", "label" : "233. Chen 2017: Recombinant Phage Elicits Protective Immune Response against Systemic S. globosa Infection in Mouse Model., Sci. Rep., 7, p. 42024, DOI: 10.1038/srep42024", "listPosition" : 233, "doi" : "10.1038/srep42024", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050869, "link" : "/api/reference/38050869", "label" : "234. Federici 2020: Phages and their potential to modulate the microbiome and immunity., Cell. Mol. Immunol., 18, p. 889, DOI: 10.1038/s41423-020-00532-4", "listPosition" : 234, "doi" : "10.1038/s41423-020-00532-4", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050870, "link" : "/api/reference/38050870", "label" : "235. Mu 2021: Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection., Microbiome, 9, p. 92, DOI: 10.1186/s40168-021-01026-9", "listPosition" : 235, "doi" : "10.1186/s40168-021-01026-9", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050871, "link" : "/api/reference/38050871", "label" : "236. Sartorius 2015: Antigen delivery by filamentous bacteriophage fd displaying an anti- DEC -205 single-chain variable fragment confers adjuvanticity by triggering a TLR 9-mediated immune response., EMBO Mol. Med., 7, p. 973, DOI: 10.15252/emmm.201404525", "listPosition" : 236, "doi" : "10.15252/emmm.201404525", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050872, "link" : "/api/reference/38050872", "label" : "237. Won 2018: A Salmonella Typhi ghost induced by the E gene of phage φX174 stimulates dendritic cells and efficiently activates the adaptive immune response., J. Veter. Sci., 19, p. 536, DOI: 10.4142/jvs.2018.19.4.536", "listPosition" : 237, "doi" : "10.4142/jvs.2018.19.4.536", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050873, "link" : "/api/reference/38050873", "label" : "238. Paule, A., Frezza, D., and Edeas, M. (2018). Microbiota and Phage Therapy: Future Challenges in Medicine. Med. Sci., 6., DOI: 10.3390/medsci6040086", "listPosition" : 238, "doi" : "10.3390/medsci6040086", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050874, "link" : "/api/reference/38050874", "label" : "239. Barr 2019: Precision Engineers: Bacteriophages Modulate the Gut Microbiome and Metabolome., Cell Host Microbe, 25, p. 771, DOI: 10.1016/j.chom.2019.05.010", "listPosition" : 239, "doi" : "10.1016/j.chom.2019.05.010", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 38050875, "link" : "/api/reference/38050875", "label" : "240. Baaziz 2022: Rehabilitation of a misbehaving microbiome: Phages for the remodeling of bacterial composition and function., Iscience, 25, p. 104146, DOI: 10.1016/j.isci.2022.104146", "listPosition" : 240, "doi" : "10.1016/j.isci.2022.104146", "published" : false, "snippet" : true } ], "hasCitationDuplums" : false, "inSelectedPubs" : "10050618", "userChangeableUntil" : "2023-02-06T07:41:28.686+0000", "directInstitutesForSort" : "Anatómiai, Szövet- és Fejlődéstani Intézet (SE / AOK / I); Transzlációs Medicina Intézet (SE / AOK / I)", "ownerAuthorCount" : 4, "ownerInstituteCount" : 11, "directInstituteCount" : 2, "authorCount" : 8, "contributorCount" : 0, "hasQualityFactor" : true, "link" : "/api/publication/33617075", "label" : "Dora David et al. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. (2023) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 24 3", "template" : "